Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol Post published:May 4, 2021 Post category:Press Release
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC Post published:April 29, 2021 Post category:Press Release
Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab Post published:April 26, 2021 Post category:Press Release
Numinus Deep Dive: Developing and Delivering Psychedelic-Assisted Psychotherapies Post published:March 23, 2021 Post category:Analysis/Editorial
Numinus Announces Closing of $40-Million Bought Deal Financing Post published:March 19, 2021 Post category:Press Release
Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 million Post published:March 15, 2021 Post category:Press Release
Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering Post published:March 15, 2021 Post category:Press Release
Numinus to expand state-of-the-art psychedelics research laboratory Post published:March 9, 2021 Post category:Press Release
Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research Post published:March 4, 2021 Post category:Press Release
OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development Post published:March 2, 2021 Post category:Press Release